VITAL: Vanguard Investigations of Therapeutic Approaches to Lung Cancer

摘要

The VITAL Research Program will provide a better understanding of the cellular and molecular processes that drive lung tumorigenesis so that an accurate risk model for recurrence and/or the development of the secondary primary tumor can be developed, and the biologic agents most effective in reducing these events in the group of high-risk patients can be identified. We will be incorporating retrospective clinical trial specimens to develop our risk model and validating it with specimens collected from our Vanguard study. The research projects are proceeding well as proposed, producing valuable findings with cell lines, and will validate these results using the clinical samples obtained from the VITAL trials in the coming years.